A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.
Vecima Networks Inc. (TSX: VCM) today reported financial results for the three and six months ended December 31, 2025.
Criteo S.A. (NASDAQ:CRTO) Q4 2025 Earnings Call Transcript February 11, 2026 Criteo S.A. misses on earnings expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results